Navigation Links
ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
Date:2/25/2008

ents that allow for sufficient delivery of immune binders into all segments of the eye via eye drops."

Dr. Escher added, "These exciting results provide the basis to proceed into clinical development later this year. Based on these pharmacodynamic properties, in combination with the reported concentrations of relevant cytokines from patients, we are confident that we can hit the therapeutic window in the chosen ophthalmic indication."

About Antibody Fragments

Antibody fragments are an emerging area of focus within the monoclonal antibody market and represent a new class of therapeutics. Due to their smaller molecular size, antibody fragments have a number of advantages over whole antibodies. Antibody fragments comprise only the naturally occurring antigen-binding pocket of the monoclonal antibody, and not the Fc part that is required to trigger an immune response. This new class of new products opens applications which are advantageous compared to monoclonal antibodies in indications where no such immune response is required. Thus, endogenous proteins are preferred targets for these new biologics.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest and VI Partners. For more information about ESBATech, please visit, http
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
2. Vaccinex Antibody Licensed to GlaxoSmithKline
3. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
4. Human Genome Sciences and Xencor Announce Antibody Collaboration
5. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
6. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
7. Roche Files IND for Second Genmab Antibody
8. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
9. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
10. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
11. Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Amarin Corporation plc,(NASDAQ: AMRND ) today announced that, ... 1 for 10 reverse split of each of its ... close of business,yesterday, January 17, 2008., Thomas Lynch, ... pleased to report that over 95% of the votes ...
... ... now means that all the population is susceptible to ... the disease, - Increased concerns over "second wave" of vCJD in individuals with much ... longer incubation times - P-Capt(R) prion reduction filter still the only proven method of protecting ...
... Calif. University of California, Irvine researchers have identified ... cerebral cortex, a finding that could lead to stem ... as stroke and Alzheimers. , Dr. Edwin Monuki, doctoral ... of Pathology & Laboratory Medicine and Developmental & Cell ...
Cached Biology Technology:Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 2Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 3Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 4Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 5Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 6Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 7Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 8Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 9ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 2ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 4ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 5Discovery of 'creator' gene for cerebral cortex points to potential stem cell treatments 2
(Date:7/11/2014)... Shenzhen, China Researchers from Salk Institute for Biological ... time evaluated the safety and reliability of the ... a new method, TALEN-HDAdV, which could significantly increased ... (hiPSC). This study published online in Cell ... for stem cell-based gene therapy. , The combination ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... 4, 2013   MedNet Solutions , a global life ... is pleased to announce its sponsorship of, participation in, ... 10-13 in Chicago .  MedNet is ... conference...the largest and most prestigious clinical data management event ...
... anti-cancer drugs and other medicines inside soil microbes and other ... given humanity more than 50 percent of today,s prescription drugs. ... cover story in Chemical & Engineering News , the ... Jarvis, C&EN senior editor, points out that natural products are ...
... useful medical information beyond what current newborn screening already ... being funded by the Eunice Kennedy Shriver National Institute ... National Human Genome Research Institute (NHGRI), both parts of ... to four grantees have been made in fiscal year ...
Cached Biology News:MedNet Solutions To Sponsor The SCDM Annual Conference For The Eighth Straight Year 2NIH program explores the use of genomic sequencing in newborn healthcare 2NIH program explores the use of genomic sequencing in newborn healthcare 3NIH program explores the use of genomic sequencing in newborn healthcare 4